Conference

Online Conference

October 15th – 16th, 2020
Registration is scheduled to open on August 31st, 2020.

Personalising Health Industry

Personalising Health Industry
Personalising Health Industry

For personalising health industry, it is essential to identify those factors that are critical for a transition towards business models supporting this approach, as it is in many respects fundamentally different from general practice today. In the interest of EU citizens, possible hurdles for health industry need to be identified that may impede the translation of scientific innovation into useful personalised products. An analysis along the value chain of personalised medicine development points to a high relevance of later stage aspects such as approval, provision and reimbursement as possible barriers. But also early stage aspects need consideration, like access to and sharing of population- as well as patient-specific biomedical-knowledge, differing requirements, culture and time-lines for the (co-)development of diagnostics and pharmaceuticals, as well as IP. In addition, access to financial resources for innovative new market entries as well as for established, but innovative SME shall be considered.

 

#HealthTechnology #PersonalisedHealthcare #PersonalisedMedicine #EuropeanRegions

Programme

Day 1, October 15th

12.45

Check-in to online system

13.00

Host Greetings from the Free State of Saxony

Sebastian Gemkow, State Minister Saxonian Ministry for Higher Education, Research, Culture and Tourism – Germany

13.05

Greetings from the European Commission

Jean-Luc Sanne, European Commission – Belgium

13.10

Introduction Regions4PerMed: the Project, Aim of the Conference

Gianni D’Errico, Toscana Life Sciences Foundation – Italy

Opening Session

13.20

Healthy Saxony – a Spotlight on Health Industry in Saxony

Dr. Olaf Müller, Healthy Saxony e.V. – Germany

13.30

Biosaxony – Supporting the Innovation Arena for Health Industry in Saxony

André Hofmann, Biosaxony e.V. – Germany

13.40

Key Note: Personalising Health Industry from an Educated Patient Perspective – a View on Hopes, Expectations, Hurdles

Prof. Joanne Hackett, BIOS Health – United Kingdom

14.00

Q&A

14.15

Short Break

Session I

Paving the Way: Infrastructures, R&D Approaches

14.30

Next Generation Biobanking – Biobanks as Potential Time Machines – a Vision for the Future

Prof. Michael Hummel, Charité Universitätsmedizin Berlin, German Biobank Node – Germany

14.45

Integration of Real-World Data in Healthcare

Mario Braga, Agenzia Regionale Sanità, Tuscany Region – Italy

15.00

The concept of N=1 trials: a Source of Deep Insight for Personalized Interventions?

Prof. Nicholas J. Schork, TGen – United States of America

15.15

Do we need to rethink Evidence Generation for Personalised Medicine?

Prof. Hans-Georg Eichler, European Medicines Agency (EMA) – The Netherlands

 

15.30

Q&A

15.50

Short Break

Session II

Setting the Scene: Aspects of Commercialisation, Product Strategies and Business Models

16.00

The Benefits and Challenges of Personalised Diagnostics

Jonathan Arnold, Qiagen – United States of America

16.15

Personalised Diagnostics as Driver for Personalised Medicine: a Synergistic Business Model

Dr. Norman Gerstner, Molecular Diagnostics Group – Germany

16.30

Personalized Medicine and Health – Challenges and Barriers from the Perspective of a Big Pharmaceutical Company

Giovanni Giuliani, Roche SpA – Italy

16.45

Personalised Medicine in Germany – Current Status and Outlook

Dr. Thorsten Ruppert, vfa – Germany

17.00

Q&A

17.20

Wrap-up

End of Day One

Day 2, October 16th

09.00

Check-in to online system

09.15

Presentation Regions4PerMed: the Project, Aim of the Conference, Summarized Highlights of Day 1

Gianni D’Errico, Toscana Life Sciences Foundation – Italy

Session III

Making it real: Intellectual Property, Funding and Institutional Support

 

09.30

Challenges of Intellectual Property Protection in Personalised Medicine

Prof. Anne Lauber-Rönsberg, Technische Universität Dresden – Germany

Dr. Sven Hetmank, Technische Universität Dresden – Germany

09.45

Good Translational Practice: a Supportive Environment for Innovative Life Sciences Companies

Dr. Siegfried Bialojan, EY – Germany

10.00

European Biotech-Clusters as Supporters of Translation

Anaïs Le Corvec, CEBR – Belgium

10.15

Q&A

10.35

Short Break

Session IV

Reaching the patient: Regulatory Aspects, Valorisation, Medical Societies, Patient Trust

10.50

Facilitating patient-led initiative with Industry – Patient Registry Data Access

Dr. Anna Ambrosini, Fondazione Telethon – Italy

11.05

Valorising Personalised Medicine and Therapeutics

Prof. Apostolos Tsiachristas, University of Oxford, HEcoPerMed – United Kingdom

11.20

Integrating Personalised Approaches into Medical Guidelines in the Field of Oncology 

Dr. Markus Follmann, MPH, MSc, Deutsche Krebsgesellschaft – Germany

11.35

Patient Education and Trust: Guidance and Support in an increasingly complex Therapeutic Setting – the Example of “Onkolotse”

Dr. Ralf Porzig, Sächsische Krebsgesellschaft e.V. – Germany

11.50

Q&A

12.10

Wrap-Up

End of the Conference